Mylan garners FDA approval for generic version of antiviral Retrovir

Mylan on Thursday announced that the FDA approved its generic version of ViiV Healthcare's Retrovir (zidovudine) for the treatment of children with HIV/AIDS and for the prevention of mother-to-child HIV transmission under the President's Emergency Plan for AIDS Relief (PEPFAR) programme.

The pediatric antiretroviral, which the company says is the first of its kind in water-dispersible tablet form, will be eligible for purchase outside the US in certain developing countries.

To read more Top Story articles, click here.